Published in J Clin Oncol on July 01, 1991
Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol (2006) 0.91
Dephosphorylation and biodistribution of 1-¹³C-phospholactate in vivo. J Labelled Comp Radiopharm (2014) 0.90
Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int J Cancer (2012) 0.89
Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer (2012) 0.89
Cancer vaccines: Looking to the future. Oncoimmunology (2013) 0.88
Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma. Int J Cancer (2013) 0.85
Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen. Transl Oncol (2011) 0.84
The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenetics (2015) 0.81
Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma. J Cancer Res Clin Oncol (2014) 0.78
Tumor markers of prognosis. J Clin Oncol (1991) 0.77
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
MUCI positive cutaneous metastasis with transepidermal elimination from a breast carcinoma. Int Med Case Rep J (2013) 0.75
Immunohistochemical expression of the mucin-type glycoprotein A-80 and prognosis in human breast cancer. Br J Cancer (1993) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
Ribosome gymnastics--degree of difficulty 9.5, style 10.0. Cell (1990) 4.01
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Eliminating language barriers for non-English-speaking patients. Med Care (1996) 3.10
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Recoding: reprogrammed genetic decoding. Science (1992) 2.92
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol (2000) 2.78
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Genomic sequence of hyperthermophile, Pyrococcus furiosus: implications for physiology and enzymology. Methods Enzymol (2001) 2.67
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med (1995) 2.63
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med (1993) 2.55
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Template-switching during DNA synthesis by Thermus aquaticus DNA polymerase I. Nucleic Acids Res (1995) 2.46
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology (2008) 2.44
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol (1984) 2.35
Correlation of defense gene induction defects with powdery mildew susceptibility in Arabidopsis enhanced disease susceptibility mutants. Plant J (1998) 2.33
Multiple forms of nuclear deoxyribonucleic acid polymerases and their relationship with the soluble enzyme. Biochem J (1973) 2.32
Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases. Am J Epidemiol (1980) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med (1996) 2.18
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Genetic screen for cloned release factor genes. J Bacteriol (1984) 2.09
Evidence for secular trends in children's physical activity behaviour. Br J Sports Med (2005) 2.07
A new venous prosthesis. Surgery (1972) 2.01
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res (2000) 1.99
Lymphocytic mastopathy. An autoimmune disease of the breast? Am J Clin Pathol (1990) 1.98
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood (1998) 1.95
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
Divergence of the hyperthermophilic archaea Pyrococcus furiosus and P. horikoshii inferred from complete genomic sequences. Genetics (1999) 1.94
Epithelioid haemangioma-like vascular proliferation in AIDS: manifestation of cat scratch disease bacillus infection? Lancet (1988) 1.92
National study of colorectal cancer genetics. Br J Cancer (2007) 1.92
Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med (2000) 1.91
Only one of two closely related yeast suppressor tRNA genes contains an intervening sequence. Nature (1981) 1.87
Transcriptional slippage occurs during elongation at runs of adenine or thymine in Escherichia coli. Nucleic Acids Res (1990) 1.87
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Cytarabine and neurologic toxicity. J Clin Oncol (1991) 1.64
Antenatal diagnosis of thalassaemia major. Br Med J (1978) 1.64
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature (1986) 1.63
Towards a genetic dissection of the basis of triplet decoding, and its natural subversion: programmed reading frame shifts and hops. Annu Rev Genet (1991) 1.62
Metastatic hypernephroma to the head and neck. AJNR Am J Neuroradiol (1988) 1.60
The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol (2000) 1.59
Multiple organ failure. Surg Gynecol Obstet (1977) 1.59
The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem (1998) 1.59
Duplications in the DMD gene. Hum Mutat (2006) 1.58
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst (1993) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev (1995) 1.55
The proteolytic cleavage of eukaryotic initiation factor (eIF) 4G is prevented by eIF4E binding protein (PHAS-I; 4E-BP1) in the reticulocyte lysate. EMBO J (1997) 1.54
Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A (2005) 1.54
Detection in human breast carcinomas of an antigen immunologically related to a group-specific antigen of mouse mammary tumor virus. Proc Natl Acad Sci U S A (1978) 1.51
Reduction in Legionella pneumophila through heat flushing followed by continuous supplemental chlorination of hospital hot water. J Infect Dis (1990) 1.51
Properties of retrovirus-like particles produced by a human breast carcinoma cell line: immunological relationship with mouse mammary tumor virus proteins. Proc Natl Acad Sci U S A (1984) 1.50
Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol (1999) 1.49
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol (1996) 1.49
Carcinoembryonic antigen: immunohistologic identification in invasive and intraepithelial carcinomas of the lung. Arch Pathol Lab Med (1977) 1.48
An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosom Med (1992) 1.48
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem (2000) 1.47
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat (2001) 1.46
Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine Tob Res (2000) 1.46
Suramin-induced skin reactions. Arch Dermatol (1992) 1.45
Cholecystectomy with and without surgical drainage. Am J Surg (1975) 1.44
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer (1992) 1.44
Sex differences in interaction style as a product of perceived sex differences in competence. J Pers Soc Psychol (1986) 1.42
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol (1995) 1.42
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics (1990) 1.40
Predicting the course of Gompertzian growth. Nature (1976) 1.39
Endoscopic versus operative gastrostomy: final results of a prospective randomized trial. Gastrointest Endosc (1990) 1.39